# Medicinova Inc: financial statements, quarterly

MNOV · Nasdaq · CIK 1226616 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mnov.md) · [Financials](/companies/mnov/financials.md) · [Filings](/companies/mnov/filings.md) · [Insiders](/companies/mnov/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mnov/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [1,000](/filings/0000950170-24-126343.md) | [0.0 d](/filings/0000950170-25-023301.md) | not reported | not reported | not reported | not reported | not reported | [135](/filings/0001193125-26-349323.md) | [123](/filings/0001193125-25-277779.md) | [152 d](/filings/0001193125-26-100432.md) | [187](/filings/0001193125-26-224066.md) | [458](/filings/0001193125-26-349323.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [700](/filings/0000950170-24-126343.md) | [1,600 d](/filings/0000950170-25-023301.md) | [1,700](/filings/0000950170-25-070461.md) | [1,500](/filings/0000950170-25-109041.md) | [1,800](/filings/0001193125-25-277779.md) | [1,800 d](/filings/0001193125-26-100432.md) | [1,700](/filings/0001193125-26-224066.md) | [2,000](/filings/0001193125-26-349323.md) | [1,500](/filings/0001193125-25-277779.md) | [1,400 d](/filings/0001193125-26-100432.md) | [1,200](/filings/0001193125-26-224066.md) | [900](/filings/0001193125-26-349323.md) |
| Operating income | $k | [(1,147)](/filings/0000950170-24-126343.md) | [(2,490) d](/filings/0000950170-25-023301.md) | [(3,136)](/filings/0000950170-25-070461.md) | [(3,046)](/filings/0000950170-25-109041.md) | [(3,309)](/filings/0001193125-25-277779.md) | [(3,184) d](/filings/0001193125-26-100432.md) | [(3,203)](/filings/0001193125-26-224066.md) | [(3,607)](/filings/0001193125-26-349323.md) | [(3,381)](/filings/0001193125-25-277779.md) | [(3,092) d](/filings/0001193125-26-100432.md) | [(2,836)](/filings/0001193125-26-224066.md) | [(2,541)](/filings/0001193125-26-349323.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(723)](/filings/0000950170-24-126343.md) | [(2,059) d](/filings/0000950170-25-023301.md) | [(2,755)](/filings/0001193125-25-277779.md) | [(2,628)](/filings/0001193125-25-277779.md) | [(2,852)](/filings/0001193125-25-277779.md) | [(2,815) d](/filings/0001193125-26-100432.md) | [(2,864)](/filings/0001193125-26-349323.md) | [(3,281)](/filings/0001193125-26-349323.md) | [(3,050)](/filings/0001193125-25-277779.md) | [(2,802) d](/filings/0001193125-26-100432.md) | [(2,586)](/filings/0001193125-26-349323.md) | [(2,314)](/filings/0001193125-26-349323.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0000950170-24-126343.md) | not reported | [(0.06)](/filings/0000950170-25-070461.md) | [(0.05)](/filings/0000950170-25-109041.md) | [(0.06)](/filings/0001193125-25-277779.md) | not reported | [(0.06)](/filings/0001193125-26-224066.md) | [(0.07)](/filings/0001193125-26-349323.md) | [(0.06)](/filings/0001193125-25-277779.md) | not reported | [(0.05)](/filings/0001193125-26-224066.md) | [(0.05)](/filings/0001193125-26-349323.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0000950170-24-126343.md) | not reported | [(0.06)](/filings/0000950170-25-070461.md) | [(0.05)](/filings/0000950170-25-109041.md) | [(0.06)](/filings/0001193125-25-277779.md) | not reported | [(0.06)](/filings/0001193125-26-224066.md) | [(0.07)](/filings/0001193125-26-349323.md) | [(0.06)](/filings/0001193125-25-277779.md) | not reported | [(0.05)](/filings/0001193125-26-224066.md) | [(0.05)](/filings/0001193125-26-349323.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [51.5](/filings/0000950170-23-062079.md) | [51.0](/filings/0000950170-25-023301.md) | [47.1](/filings/0000950170-24-056996.md) | [44.3](/filings/0000950170-24-094092.md) | [42.3](/filings/0000950170-24-126343.md) | [40.4](/filings/0001193125-26-100432.md) | [36.6](/filings/0000950170-25-070461.md) | [34.3](/filings/0000950170-25-109041.md) | [32.6](/filings/0001193125-25-277779.md) | [30.8](/filings/0001193125-26-349323.md) | [27.3](/filings/0001193125-26-224066.md) | [25.4](/filings/0001193125-26-349323.md) |
| Current assets | $m | [53.0](/filings/0000950170-23-062079.md) | [51.2](/filings/0000950170-25-023301.md) | [47.9](/filings/0000950170-24-056996.md) | [45.5](/filings/0000950170-24-094092.md) | [43.3](/filings/0000950170-24-126343.md) | [41.1](/filings/0001193125-26-100432.md) | [37.7](/filings/0000950170-25-070461.md) | [35.1](/filings/0000950170-25-109041.md) | [32.9](/filings/0001193125-25-277779.md) | [31.0](/filings/0001193125-26-349323.md) | [28.1](/filings/0001193125-26-224066.md) | [25.9](/filings/0001193125-26-349323.md) |
| Total assets | $m | [68.1](/filings/0000950170-23-062079.md) | [66.3](/filings/0000950170-25-023301.md) | [62.9](/filings/0000950170-24-056996.md) | [60.4](/filings/0000950170-24-094092.md) | [58.1](/filings/0000950170-24-126343.md) | [55.9](/filings/0001193125-26-100432.md) | [52.4](/filings/0000950170-25-070461.md) | [49.8](/filings/0000950170-25-109041.md) | [47.6](/filings/0001193125-25-277779.md) | [45.6](/filings/0001193125-26-349323.md) | [42.7](/filings/0001193125-26-224066.md) | [40.4](/filings/0001193125-26-349323.md) |
| Current liabilities | $m | [2.8](/filings/0000950170-23-062079.md) | [3.3](/filings/0000950170-25-023301.md) | [2.5](/filings/0000950170-24-056996.md) | [2.5](/filings/0000950170-24-094092.md) | [2.6](/filings/0000950170-24-126343.md) | [3.0](/filings/0001193125-26-100432.md) | [2.1](/filings/0000950170-25-070461.md) | [2.6](/filings/0000950170-25-109041.md) | [3.3](/filings/0001193125-25-277779.md) | [3.8](/filings/0001193125-26-349323.md) | [3.1](/filings/0001193125-26-224066.md) | [3.0](/filings/0001193125-26-349323.md) |
| Total liabilities | $m | [3.5](/filings/0000950170-23-062079.md) | [3.9](/filings/0000950170-25-023301.md) | [3.1](/filings/0000950170-24-056996.md) | [3.0](/filings/0000950170-24-094092.md) | [3.1](/filings/0000950170-24-126343.md) | [3.4](/filings/0001193125-26-100432.md) | [2.5](/filings/0000950170-25-070461.md) | [3.0](/filings/0000950170-25-109041.md) | [3.6](/filings/0001193125-25-277779.md) | [4.0](/filings/0001193125-26-349323.md) | [3.3](/filings/0001193125-26-224066.md) | [3.2](/filings/0001193125-26-349323.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [64.7](/filings/0000950170-24-126343.md) | [62.4](/filings/0001193125-26-100432.md) | [59.8](/filings/0001193125-25-277779.md) | [57.4](/filings/0001193125-25-277779.md) | [55.1](/filings/0001193125-25-277779.md) | [52.5](/filings/0001193125-26-349323.md) | [49.9](/filings/0001193125-26-349323.md) | [46.9](/filings/0001193125-26-349323.md) | [44.0](/filings/0001193125-25-277779.md) | [41.6](/filings/0001193125-26-349323.md) | [39.4](/filings/0001193125-26-349323.md) | [37.3](/filings/0001193125-26-349323.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,372) d](/filings/0000950170-24-126343.md) | [(499) d](/filings/0000950170-25-023301.md) | [(3,868)](/filings/0000950170-25-070461.md) | [(2,811) d](/filings/0000950170-25-109041.md) | [(2,032) d](/filings/0001193125-25-277779.md) | [(1,932) d](/filings/0001193125-26-100432.md) | [(3,784)](/filings/0001193125-26-224066.md) | [(2,306) d](/filings/0001193125-26-349323.md) | [(1,703) d](/filings/0001193125-25-277779.md) | [(2,017) d](/filings/0001193125-26-100432.md) | [(3,470)](/filings/0001193125-26-224066.md) | [(1,920) d](/filings/0001193125-26-349323.md) |
| Capital expenditure | $k | [2.7 d](/filings/0000950170-24-126343.md) | [(0.0) d](/filings/0000950170-25-023301.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-277779.md) | [(0.0) d](/filings/0001193125-26-100432.md) | [0.0](/filings/0001193125-26-224066.md) | [0.0 d](/filings/0001193125-26-349323.md) | [2.9 d](/filings/0001193125-25-277779.md) | [0.0 d](/filings/0001193125-26-100432.md) | [10.8](/filings/0001193125-26-224066.md) | [0.0 d](/filings/0001193125-26-349323.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q1 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [49.0](/filings/0000950170-23-062079.md) | [49.0](/filings/0000950170-24-056996.md) | [49.0](/filings/0000950170-24-094092.md) | [49.0](/filings/0000950170-24-126343.md) | [49.0](/filings/0000950170-25-070461.md) | [49.0](/filings/0000950170-25-109041.md) | [49.0](/filings/0001193125-25-277779.md) | [49.0](/filings/0001193125-26-224066.md) | [49.0](/filings/0001193125-26-349323.md) | [49.0](/filings/0001193125-25-277779.md) | [49.2](/filings/0001193125-26-224066.md) | [49.2](/filings/0001193125-26-349323.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,221,246 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349323.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.